Fulcrum Therapeutics (FULC) Net Income towards Common Stockholders (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Net Income towards Common Stockholders of -$35.0 million for Q2 2026, down 102.27% year-over-year from $1.5 billion in Q2 2025, and up 29.98% quarter-over-quarter from -$50.0 million in Q1 2026.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Net Income towards Common Stockholders for 9 consecutive years, with -$35.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders fell 102.27% year-over-year to -$35.0 million; the TTM figure through Jun 2026 stood at -$188.7 million (down 101.92% YoY), while the FY2025 annual figure was -$161.2 million, down 119.71% from the prior year.
- Net Income towards Common Stockholders grew to -$35.0 million in Q2 2026 per FULC's latest filing, from -$50.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $55.4 million in Q2 2024 and bottomed at -$94.0 million in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged -$35.5 million across 5 years, with a median of -$32.4 million in 2022.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 332.98% — and 2025, when it slumped 236.18%.
- Fulcrum Therapeutics' Net Income towards Common Stockholders stood at -$29.9 million in 2022, then slumped by 44.37% to -$43.1 million in 2023, then soared by 41.93% to -$25.0 million in 2024, then plunged by 236.18% to -$84.2 million in 2025, then soared by 58.43% to -$35.0 million in 2026.
- Business Quant data shows FULC's Net Income towards Common Stockholders at -$35.0 million in Q2 2026, -$50.0 million in Q1 2026, and -$84.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - | -26.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.18 Mn |
| Mar 31, 2026 | -22.87 Mn |
| Dec 31, 2025 | -20.33 Mn |
| Sep 30, 2025 | -19.60 Mn |
| Jun 30, 2025 | -17.30 Mn |
| Mar 31, 2025 | -20.46 Mn |
| Dec 31, 2024 | -16.57 Mn |
| Sep 30, 2024 | -21.70 Mn |
| Jun 30, 2024 | 55.41 Mn |
| Mar 31, 2024 | -30.13 Mn |
| Dec 31, 2023 | -24.76 Mn |
| Sep 30, 2023 | -24.02 Mn |
| Jun 30, 2023 | -23.78 Mn |
| Mar 31, 2023 | -27.79 Mn |
| Dec 31, 2022 | -26.14 Mn |
| Sep 30, 2022 | -23.74 Mn |
| Jun 30, 2022 | -34.21 Mn |
| Mar 31, 2022 | -26.69 Mn |
| Dec 31, 2021 | -24.09 Mn |
| Sep 30, 2021 | -20.72 Mn |